## **Steve Kopko**

From: COADataStandards < COADataStandards@fda.hhs.gov>

Wednesday, June 3, 2020 1:44 PM Sent:

To: Steve Kopko; Dana Booth

Conley, Chenoa; Jimenez, Sara; Garrard, Lili; Dlugash, Rachel; Sun, Liping; Wilson, Cc:

Stephen

**Subject:** FDA Comments for NSCLC & SMDDS

**Attachments:** SDTM QS NSCLC-SAQ V1.0 Approved\_FDA Comments 2020-06-03 .docx; SDTM QS

SMDDS v1.0 Approved\_FDA Comments 2020-06-03.docx

Importance: High

Hello Steve & Dana,

Please find attached NSCLC and SMDDS supplements containing FDA comments/feedback. If you have any further questions, please let me know.

Have a great day!

Regards,

## Chenoa Conley, MS

Project Manager Office of Strategic Programs, CDER U.S. Food and Drug Administration

Tel: 301-796-0035

Chenoa.Conley@fda.hhs.gov









